Navigation Links
Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts
Date:8/6/2009

The Angelman Syndrome Foundation, www.angelman.org, announced the formation of the Angelman Treatment and Research Institute (ATRI), which will direct the organization's rapidly increasing research funding. The ATRI will also serve as a hub for more than 30 organizations, researchers and scientists worldwide to share discoveries and treatments for this neuro-genetic disorder. The announcement of the ATRI was made during the Angelman Syndrome Foundation's biennial conference in Orlando, Fla.

Orlando, FL (PRWEB) August 6, 2009 -- The Angelman Syndrome Foundation, www.angelman.org, announced the formation of the Angelman Treatment and Research Institute (ATRI), which will direct the organization's rapidly increasing research funding.

News Facts Related to Angelman Syndrome and the ATRI:
- Angelman Syndrome (AS) occurs once in every 15,000 live births and exhibits symptoms such as: developmental delay; lack of speech; seizures; inappropriate laughter; and walking and balance disorders.

- ATRI will realize the Angelman Syndrome Foundation's "scientific roadmap," which will help direct its aggressive funding of AS research.

- Short term focus of the roadmap is to fund research that finds treatments that may cure symptoms of AS while continuing ongoing research and clinical trials involving UBE3A, the abnormal gene in AS patients.

- Research funding will also focus on new therapies for symptoms, pharmaceuticals, biological agents, adaptive devices, surgical and diagnostic procedures.

- An emphasis on adult AS patients will extend the scope of clinical trials to include a wide age group and investigate and advance life and self-help skills, vocational training, and access to community programs and health services.

- ATRI will allow scientific members to conduct Web-based meetings and symposiums, and convene as necessary to discuss research progress and activities.

- Since AS shares symptoms with several other disorders, including autism, cerebral palsy, epilepsy, Rett Syndrome, and Prader-Willi Syndrome, any progress toward treating and curing symptoms has the potential to positively affect more than 12 million people.

Quotes Attributed to Michael D. Ehlers, M.D., Ph.D., Department of Neurobiology at Duke University Medical Center:
- "The creation of the Angelman Treatment and Research Institute is exciting and timely.
- "The priorities as established by the ATRI are right on in recognizing the continued need for expanding our fundamental knowledge of UBE3A and its role in brain development and function."
- "The Angelman Syndrome Foundation is to be applauded for having the vision to recognize the critical importance of basic research and in setting this research on a trajectory toward a cure."
- "I see a future of great opportunity and advance in neurodevelopmental disorders with Angelman Syndrome and the ATRI leading the way."

Quotes Attributed to Eileen Braun, Angelman Syndrome Foundation Executive Director
- The Angelman Syndrome Foundation is committing $125,000 in seed funding to start ATRI with an ultimate goal of raising $2 million within two years.
- Funding will be used to implement program goals while the Angelman Syndrome Foundation's Scientific Advisory Committee will continue administering grant reviews and making funding recommendations for innovative research.

Related Links:
Angelman Syndrome Foundation Web site
Researcher Endorsements of the ATRI
Angelman Syndrome Foundation Videos

About Angelman Syndrome:
Identified by Dr. Harry Angelman, AS occurs once in every 15,000 live births and exhibits symptoms such as: developmental delay; lack of speech; seizures; inappropriate laughter; and walking and balance disorders. It is a life-long neuro-genetic disorder usually identified in patients between two and five years old. AS is often misdiagnosed as autism and a cure has not yet been developed.

About Angelman Syndrome Foundation:
The Angelman Syndrome Foundation, the leading resource for AS information, support and AS research funding was founded more than 20 years ago with the mission of advancing the awareness and treatment of AS through education and information, research and support for individuals with AS, their families and other concerned parties. Since 1996 the Angelman Syndrome Foundation has funded 51 research grants totaling over $2.5 million. The Angelman Syndrome Foundation has awarded a majority of these funds ($2.2 million) beginning in 2005. In November 2008, the Angelman Syndrome Foundation received Charity Navigator's 4-star rating for sound fiscal management. Only a quarter of all charities evaluated by Charity Navigator receive this distinction of demonstrating the ability to efficiently manage and grow its finances.

###

Read the full story at http://www.prweb.com/releases/2009/08/prweb2706254.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts
2. Diabetes appears to increase risk of death for patients with acute coronary syndromes
3. Eye-staining technique offers early detection for dry eye syndrome
4. Pollen, Fruits, Veggies Help Trigger Oral Allergy Syndrome
5. Treating depression may improve recovery of heart rate variability following coronary syndromes
6. Stem cell research produces a key discovery for Fragile X Syndrome
7. Metabolic syndrome heightens risk for development of uric-acid kidney stones
8. Stomach Virus a Culprit in Chronic Fatigue Syndrome
9. Chronic fatigue syndrome linked to stomach virus
10. Toward a faster prenatal test for Down syndrome
11. Brain Defect Helps Drive Fragile X Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Angelman Syndrome Foundation Takes Major Step Toward Furthering Research Efforts
(Date:2/24/2017)... ... ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 top five ... art competition. Selected from 15 submissions from around the nation, the top five finalists ... iaedp Symposium, March 22 – 26 in Las Vegas. , This year, the competition ...
(Date:2/24/2017)... ... February 24, 2017 , ... Castle ... hosted their Military Wedding Giveaway, with the winning couple announced on Feb. 14, ... services generously donated from local vendors: A Matter of Taste, Ryan Rousseau Enterprises, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... a clinician-based audience, will be participating in Rare Disease Day events, hosted by ... In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will ...
(Date:2/23/2017)... Mass. (PRWEB) , ... February 23, 2017 , ... ... as an approved content provider for the National Institute for Health and ... and social care-related organizations in the National Health Service (NHS) to search, order ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... announced today that it will soon begin franchising throughout the U.S. starting this ... to help bring the practice of meditation mainstream. Current Meditation will be the ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... BRISBANE, Australia , Feb. 23, 2017  Directors from Pharma ... the two companies have joined forces, resulting in the founding of ... . Pharma To Market are pleased to announce their ... an office in Singapore . The company are ... Consulting as Co-Director of the Singapore based ...
(Date:2/24/2017)... Feb 24, 2017 Medivir AB ... for a new Board of Directors that will be ... Nomination Committee comprises representatives of the company,s three largest ... 2016 who have accepted a seat on the Nomination ... of the 2016-2017 Nomination Committee was as follows:  ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Autism ... to their offering. ... The latest research Autism Spectrum Disorder Drugs Price Analysis and ... global Autism Spectrum Disorder market. The research answers the following ... marketed for Autism Spectrum Disorder and their clinical attributes? How are ...
Breaking Medicine Technology: